Artelo Biosciences Inc. Common Stock (ARTL)
Stock · NASDAQ · Health Care
$2.7as of 10/16/2026
Price chart
Active signals
ARTL Signal Track Record
How signals performed across all stocks →What ARTL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 24 | -2.7% | 50% | August 27, 2026 |
| Bollinger Band Breakout | 21 | -14.7% | 19% | August 31, 2026 |
| Volume Spike | 12 | -24.7% | 25% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -15.9% | 20% | October 8, 2026 |
| Any 20-session window (baseline) | -6.0% | 35% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 7
- Website
- artelobio.com/
Fundamentals
- 1-day range
- $3.11$3.25
- Market cap
- $2.62M
- P/E (trailing)
- —
- P/E (forward)
- -3.53
- EPS (trailing)
- $-22.97
- Dividend yield
- —
- Beta
- -0.11
- Avg. volume
- 474.1K
- Dividend pay date
- June 21, 2019
Artelo Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ARTLArtelo Biosciences Inc. Common Stock$2.7▼ 1.46%Market cap $2.62MP/E —$2.92$179.19
- CDTCDT Equity Inc. Common Stock$0.235▲ 12.44%Market cap $2.54MP/E —$0.1813$28,125
- GRIGRI Bio Inc. Common Stock$1.38▼ 1.43%Market cap $2.74MP/E 0.04$1.36$64.12
- SHPHShuttle Pharmaceuticals Holdings Inc. Common Stock$5.08▼ 8.80%Market cap $2.79MP/E 43.60$2.58$55.9
- OGENOragenics Inc. Common Stock$0.43▼ 2.27%Market cap $2.45MP/E 0.56$0.43$1.45
- DCOYDecoy Therapeutics Inc. Common Stock$1.17▼ 4.88%Market cap $2.40MP/E —$2.01$55.92
- PPBTPurple Biotech Ltd. American Depositary Shares$1.14▼ 7.32%Market cap $2.29MP/E —$1$2.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ARTL Artelo Biosciences Inc. Common Stock | $2.62M | — | $2.7 | ▼ 1.46% | $2.92$179.19 |
| CDT CDT Equity Inc. Common Stock | $2.54M | — | $0.235 | ▲ 12.44% | $0.1813$28,125 |
| GRI GRI Bio Inc. Common Stock | $2.74M | 0.04 | $1.38 | ▼ 1.43% | $1.36$64.12 |
| SHPH Shuttle Pharmaceuticals Holdings Inc. Common Stock | $2.79M | 43.60 | $5.08 | ▼ 8.80% | $2.58$55.9 |
| OGEN Oragenics Inc. Common Stock | $2.45M | 0.56 | $0.43 | ▼ 2.27% | $0.43$1.45 |
| DCOY Decoy Therapeutics Inc. Common Stock | $2.40M | — | $1.17 | ▼ 4.88% | $2.01$55.92 |
| PPBT Purple Biotech Ltd. American Depositary Shares | $2.29M | — | $1.14 | ▼ 7.32% | $1$2.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor PlatformYahoo · 10/7/2026
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · 9/25/2026
- Keep an eye on the top gainers and losers in Thursday's session.ChartMill · 9/24/2026
- Which stocks are moving on Thursday?ChartMill · 9/24/2026
- The market is filled with gapping stocks in Thursday's session.ChartMill · 9/24/2026
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga · 9/24/2026
- Wondering what's happening in today's pre-market session?ChartMill · 9/24/2026
- Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000Benzinga · 9/24/2026
Insider Activity
Insider Actions →- Blayney Douglas · July 17, 2026 · Grant136
- Reyes Gregory · July 17, 2026 · Grant136
- Kelly Steven · July 17, 2026 · Grant136
- FAVORITO TAMARA A · July 17, 2026 · Grant136
- Connie Matsui · July 17, 2026 · Grant136
- EMANUELE ROBERT MARTIN · July 17, 2026 · Grant136
Institutional Ownership
March 31, 2026
- Total shares held
- 42.5K
- Total value held
- $321.9K
- Institutional holders
- 9
- Unknown13.3K
- Unknown13.1K
- Unknown10.1K
- Unknown3.1K
- Unknown2.8K
- Unknown100
- Unknown2
- Unknown1
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
ARTL Selected for First Company Presentation at BIO‑Europe 2026
Artelo Biosciences has been chosen to present at BIO‑Europe 2026. The company will discuss clinical progress and the potential of its FABP5 inhibitor platform. This event highlights growing interest in the drug candidate and may increase visibility among researchers and investors. The presentation is a milestone in the company's development timeline.
ARTL Selected for First Company Presentation at BIO‑Europe 2026. Artelo Biosciences has been chosen to present at BIO‑Europe 2026. The company will discuss clinical progress and the potential of its FABP5 inhibitor platform. This event highlights growing interest in the drug candidate and may increase visibility among researchers and investors. The presentation is a milestone in the company's development timeline.